Coupled with the only marginal increase in plasmatic S100A9 in decompensated patients with diabetes, our data are in favor of the development of an S100A9-based adjunctive therapeutic approach aimed at achieving better metabolic control in patients with diabetes suffering from ID. Here, S100A9 is linked to diabetes mellitus.